Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.

Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW.

Clin Cancer Res. 2019 Apr 1;25(7):2155-2165. doi: 10.1158/1078-0432.CCR-18-2792. Epub 2019 Jan 7.

PMID:
30617134
2.

Description of a reproducible anatomically based surgical algorithm for detection of pelvic sentinel lymph nodes in endometrial cancer.

Persson J, Geppert B, Lönnerfors C, Bollino M, Måsbäck A.

Gynecol Oncol. 2017 Oct;147(1):120-125. doi: 10.1016/j.ygyno.2017.07.131. Epub 2017 Jul 24.

PMID:
28751118
3.

Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas.

Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW.

Am J Surg Pathol. 2017 Sep;41(9):1231-1237. doi: 10.1097/PAS.0000000000000894.

PMID:
28622181
4.

Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.

Arildsen NS, Jönsson JM, Bartuma K, Ebbesson A, Westbom-Fremer S, Måsbäck A, Malander S, Nilbert M, Hedenfalk IA.

Front Oncol. 2017 May 29;7:109. doi: 10.3389/fonc.2017.00109. eCollection 2017.

5.

Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.

Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.

Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.

6.

A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis.

Nastic D, Shanwell E, Wallin KL, Valla M, Måsbäck A, Mateoiu C, Lidang M, Liakka A, Lappi-Blanco E, Grove A, Davidson B, Carpen O, Bertelsen BI, Bak J, Abusland AB, Selling J, Carlson JW.

Int J Gynecol Pathol. 2017 Jul;36(4):339-347. doi: 10.1097/PGP.0000000000000334.

PMID:
28244894
7.

Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.

Jönsson JM, Skovbjerg Arildsen N, Malander S, Måsbäck A, Hartman L, Nilbert M, Hedenfalk I.

Transl Oncol. 2015 Oct;8(5):424-33. doi: 10.1016/j.tranon.2015.09.002.

8.

Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study.

Green RW, Engblom S, Baldetorp B, Hartman L, Måsbäck A, Bjurberg M.

Acta Obstet Gynecol Scand. 2015 Oct;94(10):1064-73. doi: 10.1111/aogs.12704. Epub 2015 Jul 27.

PMID:
26123703
9.

Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.

Jönsson JM, Johansson I, Dominguez-Valentin M, Kimbung S, Jönsson M, Bonde JH, Kannisto P, Måsbäck A, Malander S, Nilbert M, Hedenfalk I.

PLoS One. 2014 Sep 16;9(9):e107643. doi: 10.1371/journal.pone.0107643. eCollection 2014.

10.

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Staaf J, Harbst K, Lauss M, Ringnér M, Måsbäck A, Howlin J, Jirström K, Harland M, Zebary A, Palmer JM, Ingvar C, Olsson H, Newton-Bishop J, Hansson J, Hayward N, Gruis N, Jönsson G.

J Invest Dermatol. 2014 Dec;134(12):3000-3003. doi: 10.1038/jid.2014.272. Epub 2014 Jul 7. No abstract available.

11.

Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.

Jönsson JM, Bartuma K, Dominguez-Valentin M, Harbst K, Ketabi Z, Malander S, Jönsson M, Carneiro A, Måsbäck A, Jönsson G, Nilbert M.

Fam Cancer. 2014 Dec;13(4):537-45. doi: 10.1007/s10689-014-9728-1.

12.

Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.

Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck A, Tolf A, Gilks CB, Carlson JW.

Histopathology. 2014 Jun;64(7):1004-13. doi: 10.1111/his.12349. Epub 2014 Mar 7.

PMID:
24329781
13.

Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial.

Epstein E, Testa A, Gaurilcikas A, Di Legge A, Ameye L, Atstupenaite V, Valentini AL, Gui B, Wallengren NO, Pudaric S, Cizauskas A, Måsbäck A, Zannoni GF, Kannisto P, Zikan M, Pinkavova I, Burgetova A, Dundr P, Nemejcova K, Cibula D, Fischerova D.

Gynecol Oncol. 2013 Mar;128(3):449-53. doi: 10.1016/j.ygyno.2012.09.025. Epub 2012 Sep 28.

PMID:
23022593
14.

Molecular profiling reveals low- and high-grade forms of primary melanoma.

Harbst K, Staaf J, Lauss M, Karlsson A, Måsbäck A, Johansson I, Bendahl PO, Vallon-Christersson J, Törngren T, Ekedahl H, Geisler J, Höglund M, Ringnér M, Lundgren L, Jirström K, Olsson H, Ingvar C, Borg Å, Tsao H, Jönsson G.

Clin Cancer Res. 2012 Aug 1;18(15):4026-36. doi: 10.1158/1078-0432.CCR-12-0343. Epub 2012 Jun 6. Erratum in: Clin Cancer Res. 2012 Oct 15;18(20):5829. Höglund, Markus [corrected to Höglund, Mattias]; Ringnér, Mattias [corrected to Ringnér, Markus].

15.

A prospective, population-based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma.

Nielsen K, Måsbäck A, Olsson H, Ingvar C.

Int J Cancer. 2012 Aug 1;131(3):706-15. doi: 10.1002/ijc.26408. Epub 2011 Oct 20.

16.

Gray-scale and color Doppler ultrasound characteristics of endometrial cancer in relation to stage, grade and tumor size.

Epstein E, Van Holsbeke C, Mascilini F, Måsbäck A, Kannisto P, Ameye L, Fischerova D, Zannoni G, Vellone V, Timmerman D, Testa AC.

Ultrasound Obstet Gynecol. 2011 Nov;38(5):586-93. doi: 10.1002/uog.9038. Epub 2011 Aug 30.

17.

Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns.

Harbst K, Staaf J, Måsbäck A, Olsson H, Ingvar C, Vallon-Christersson J, Ringnér M, Borg A, Jönsson G.

Melanoma Res. 2010 Oct;20(5):381-91.

PMID:
20848731
18.

Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.

Nielsen K, Harbst K, Måsbäck A, Jönsson G, Borg A, Olsson H, Ingvar C.

Melanoma Res. 2010 Aug;20(4):266-72. doi: 10.1097/CMR.0b013e3283341339.

PMID:
20526219
19.

Problems in assessing multiple cutaneous melanoma. A review on the accuracy of a population based cancer registry.

Måsbäck A, Andersson G, Olsson H.

Cancer Epidemiol. 2010 Jun;34(3):262-6. doi: 10.1016/j.canep.2010.02.014. Epub 2010 Mar 25.

PMID:
20346747
20.

Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix.

Epstein E, Di Legge A, Måsbäck A, Lindqvist PG, Kannisto P, Testa AC.

Ultrasound Obstet Gynecol. 2010 Oct;36(4):512-6. doi: 10.1002/uog.7638.

21.

Histopathology indicates lymphatic spread of a pelvic retroperitoneal ectopic pregnancy removed by robot-assisted laparoscopy with temporary occlusion of the blood supply.

Persson J, Reynisson P, Måsbäck A, Epstein E, Saldeen P.

Acta Obstet Gynecol Scand. 2010 Jun;89(6):835-9. doi: 10.3109/00016341003623779.

PMID:
20334587
22.

The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm.

Darlin L, Persson J, Bossmar T, Lindahl B, Kannisto P, Måsbäck A, Borgfeldt C.

Gynecol Oncol. 2010 May;117(2):266-9. doi: 10.1016/j.ygyno.2010.01.035. Epub 2010 Feb 18.

PMID:
20167355
23.

Adenocarcinoma corpus uteri stage I-II: results of a treatment programme based upon cytometry.

Lindahl B, Måsbäck A, Persson J, Ranstam J, Willlén R.

Anticancer Res. 2009 Nov;29(11):4731-5.

24.

Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma.

Nielsen K, Masback A, Bladstrom A, Lundgren L, Jonsson N, Borg A, Ingvar C, Olsson H.

Br J Dermatol. 2008 Feb;158(2):429-31. Epub 2007 Nov 28. No abstract available.

PMID:
18047508
25.

Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.

Domanska K, Malander S, Måsbäck A, Nilbert M.

Int J Gynecol Cancer. 2007 Jul-Aug;17(4):789-93. Epub 2007 Mar 5.

PMID:
17343610
26.

Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer.

Borgfeldt C, Iosif C, Måsbäck A.

Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):110-4. Epub 2006 Jul 21.

PMID:
16859821
27.

Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study.

Nielsen K, Ingvar C, Måsbäck A, Westerdahl J, Borg A, Sandberg T, Jonsson N, Nagel J, Olsson H.

Br J Dermatol. 2004 Mar;150(3):531-6.

PMID:
15030338
28.

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

Malander S, Ridderheim M, Måsbäck A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A.

Eur J Cancer. 2004 Feb;40(3):422-8.

PMID:
14746861
29.

Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families.

Måsbäck A, Olsson H, Westerdahl J, Sandberg T, Borg A, Jonsson N, Ingvar C.

Melanoma Res. 2002 Dec;12(6):549-57.

PMID:
12459644
30.

Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review.

Måsbäck A, Olsson H, Westerdahl J, Ingvar C, Jonsson N.

Melanoma Res. 2001 Oct;11(5):435-45.

PMID:
11595879
32.

High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Måsbäck A, Westerdahl J, Olsson H, Ingvar C.

J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6.

PMID:
10922411
33.

Sunscreen use and malignant melanoma.

Westerdahl J, Ingvar C, Mâsbäck A, Olsson H.

Int J Cancer. 2000 Jul 1;87(1):145-50.

34.

Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity.

Westerdahl J, Ingvar C, Måsbäck A, Jonsson N, Olsson H.

Br J Cancer. 2000 May;82(9):1593-9.

35.

Clinical and histopathological characteristics in relation to aetiological risk factors in cutaneous melanoma: a population-based study.

Måsbäck A, Westerdahl J, Ingvar C, Olsson H, Jonsson N.

Melanoma Res. 1999 Apr;9(2):189-97.

PMID:
10380942
36.

Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations.

Måsbäck A, Westerdahl J, Ingvar C, Olsson H, Jonsson N.

Cancer. 1997 Jan 15;79(2):275-83.

PMID:
9010101
37.

Novel germline p16 mutation in familial malignant melanoma in southern Sweden.

Borg A, Johannsson U, Johannsson O, Häkansson S, Westerdahl J, Mäsbäck A, Olsson H, Ingvar C.

Cancer Res. 1996 Jun 1;56(11):2497-500.

38.

Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors.

Westerdahl J, Olsson H, Måsbäck A, Ingvar C, Jonsson N.

Br J Cancer. 1996 May;73(9):1126-31.

39.

Is the use of sunscreens a risk factor for malignant melanoma?

Westerdahl J, Olsson H, Måsbäck A, Ingvar C, Jonsson N.

Melanoma Res. 1995 Feb;5(1):59-65.

PMID:
7734957
40.

Use of sunbeds or sunlamps and malignant melanoma in southern Sweden.

Westerdahl J, Olsson H, Måsbäck A, Ingvar C, Jonsson N, Brandt L, Jönsson PE, Möller T.

Am J Epidemiol. 1994 Oct 15;140(8):691-9.

PMID:
7942771
41.

Cutaneous malignant melanoma in south Sweden 1965, 1975, and 1985. A histopathologic review.

Måsbäck A, Westerdahl J, Ingvar C, Olsson H, Jonsson N.

Cancer. 1994 Mar 15;73(6):1625-30.

PMID:
8156490
42.

Down syndrome. Seasonality and parity effects.

Källén B, Måsbäck A.

Hereditas. 1988;109(1):21-7. No abstract available.

Supplemental Content

Loading ...
Support Center